Duowell Pharmaceuticals Private Limited
About Duowell Pharmaceuticals Private Limited
Data last updated:
Duowell Pharmaceuticals Private Limited is a private limited company based in Delhi, India. It was incorporated on 12 January 2024.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U46497DL2024PTC425209.
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Kedar Nath Dalabehara and Shashi Dev.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Shop No. 8 Pocket II, Csc Mayur Vihar Phase – I, Delhi, India – 110091.
As per the financials filed for FY 2025, the company reported a revenue of ₹20.05 Lakh. For the same year it recorded a net profit of ₹55,227 (net margin 2.8%) and EBITDA of ₹65,634 (EBITDA margin 3.3%).
Company details
Contact details
Duowell Pharmaceuticals Private Limited's registered office is in Delhi, Delhi.
- Registered AddressShop No. 8 Pocket II, Csc Mayur Vihar Phase – I, Delhi, India – 110091
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Duowell Pharmaceuticals is wholesale and retail trade; repair of motor vehicles and motorcycles. In detail, this covers wholesale trade, except of motor vehicles and motorcycles.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Wholesale and retail trade; repair of motor vehicles and motorcycles | 46 | Wholesale trade, except of motor vehicles and motorcycles |
To see the full business activity and turnover split of Duowell Pharmaceuticals Private Limited, buy the company report.
Financials of Duowell Pharmaceuticals Private Limited
FY 2025 filings availableDuowell Pharmaceuticals Private Limited reported revenue of ₹20.05 Lakh for FY 2025.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 |
|---|---|---|
| Profit and Loss Statement | ||
| Revenue from Operations | ||
| Other Income | ||
| Total Revenue | ||
| Cost of Materials Consumed | ||
| Employee Benefit Expense | ||
| Finance Costs | ||
| Depreciation and Amortisation | ||
| Other Expenses | ||
| Total Expenses | ||
| EBITDA | ₹65,634 | |
| Profit Before Tax | ||
| Tax Expense | ||
| Net Profit (PAT) | ₹55,227 | |
| Balance Sheet | ||
| Share Capital | ||
| Reserves and Surplus | ||
| Net Worth (Total Equity) | ||
| Long-term Borrowings | ||
| Short-term Borrowings | ||
| Trade Payables | ||
| Total Liabilities | ||
| Fixed Assets | ||
| Investments | ||
| Inventories | ||
| Trade Receivables | ||
| Cash and Bank Balance | ||
| Total Assets | ||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 |
|---|---|---|
| Profitability | ||
| EBITDA Margin | 3.3% | |
| Net Profit Margin | 2.8% | |
| Return on Equity (ROE) | ||
| Return on Capital Employed (ROCE) | ||
| Return on Assets (ROA) | ||
| Liquidity and Debt | ||
| Current Ratio | ||
| Quick Ratio | ||
| Debt-to-Equity Ratio | ||
| Interest Coverage Ratio | ||
| Efficiency and Growth | ||
| Asset Turnover | ||
| Receivable Days | ||
| Payable Days | ||
| Inventory Days | ||
| Revenue Growth | ||
| Net Profit Growth | ||
To see the full financial statements and ratios of Duowell Pharmaceuticals Private Limited, buy the company report.
Board of directors of Duowell Pharmaceuticals Private Limited
Duowell Pharmaceuticals has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Kedar Nath Dalabehara | Director | 12 Jan 2024 | 2 Years 9 Months | Current |
| Shashi Dev | Director | 12 Jan 2024 | 2 Years 9 Months | Current |
Legal cases
No court or tribunal cases involving Duowell Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Duowell Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Duowell Pharmaceuticals Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Duowell Pharmaceuticals Private Limited has 2 board changes on record since 2024: 2 appointments. The latest: Kedar Nath Dalabehara was appointed as Director on 12 Jan 2024.
Frequently asked questions
Duowell Pharmaceuticals is an active private limited company based in Delhi, India. It was incorporated on 12 January 2024 (2+ years old) and is registered under CIN U46497DL2024PTC425209.
Duowell Pharmaceuticals has 2 current directors:
- Kedar Nath Dalabehara - Director
- Shashi Dev - Director
The latest financial statements of Duowell Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2024 are in the company report.
The CIN (Corporate Identification Number) of Duowell Pharmaceuticals is U46497DL2024PTC425209. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Duowell Pharmaceuticals was incorporated on 12 January 2024, making it 2+ years old. It is registered with the Registrar of Companies, Delhi.
Kedar Nath Dalabehara was appointed as Director on 12 Jan 2024. Shashi Dev was appointed as Director on 12 Jan 2024.
The registered office of Duowell Pharmaceuticals is at Shop No. 8 Pocket II, Csc Mayur Vihar Phase – I, Delhi, India – 110091.
Duowell Pharmaceuticals can be reached at its registered office: Shop No. 8 Pocket II, Csc Mayur Vihar Phase – I, Delhi, India – 110091.
Duowell Pharmaceuticals is registered under the jurisdiction of the Registrar of Companies (ROC), Delhi.